KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial.

Eugen Feist, Michael E Luggen, Evgeny L Nasonov, Sergey S Yakushin, Daria V Bukhanova, Alina N Egorova, Sergey A Grishin, Mikhail Y Samsonov, Josef S Smolen

Arthritis Res Ther 27(1) 213

PMID41239458
PMCIDPMC12619491
DOI10.1186/s13075-025-03682-w
发表日期2025-11-14
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 forest plot;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased prevalence of comorbidities, which is associated with higher RA disease activity and worse disease outcomes. The aim of this analysis was to evaluate the impact of the comorbidity burden on the efficacy of the IL-6 inhibitor olokizumab (OKZ) and the tumour necrosis factor (TNF) inhibitor adalimumab (ADA) in the CREDO-2 randomized controlled clinical trial cohort of patients with active RA. METHODS: A total of 1402 patients with RA were included in the analysis and divided into two groups on the basis of the modified Charlson Comorbidity Index (mCCI) at baseline: those having no comorbid conditions, NCC (mCCI = 1; RA only) vs. those having comorbid conditions, CC (mCCI ≥ 2; RA and ≥ 1 comorbidity). The key outcomes at Week (W) 24 were the proportions of patients with CDAI ≤ 10 and CDAI ≤ 2.8, other outcomes were ACR50 (W12, W24), proportions of patients with SDAI ≤ 3.3 (W24). RESULTS: All groups had similar proportions of approximately 25% of patients with mCCI ≥ 2. There was no significant difference in efficacy between the OKZ q4w or q2w-treated NCC and CC groups at 3 and 6 months of treatment. The same was observed for the placebo group. In contrast, comorbidities reduced CDAI ≤ 10 and ACR50 outcomes upon ADA treatment at 6 months. CONCLUSION: This post hoc analysis of the phase III CREDO-2 study suggests that the presence of at least one CCI comorbidity, including common disorders such as chronic pulmonary diseases and cardiovascular diseases, does not affect the OKZ treatment results in RA patients. In contrast, comorbidities reduce several efficacy outcomes upon ADA treatment at 6 months. The CCI was not associated with placebo group results and had no influence on safety outcomes. TRIAL REGISTRATION: NCT02760407 submitted 2016-05-02.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Predicted Probability with 95% CI from logistic regression for the key and other outcomes. Model 2. Week 24. Abbreviations: ACR 50, 50% improvement in the American College of Rheumatology criteria; ADA, adalimumab; CC, comorbid conditions; CDAI, Clinical Disease Activity Index; NCC, no comorbid conditions; OKZ, olokizumab; q2w – once every 2 weeks; q4w – once every 4 weeks, SDAI, Simplified Disease Activity Index. Note: p -value for interaction terms in logistic regression is presented
非 KM Figure
Fig. 2Fig. 2 Predicted Probability for the key and other outcomes. Model 2. Week 12. Abbreviations: ACR 50, 50% improvement in the American College of Rheumatology criteria; ADA, adalimumab; CC, comorbid conditions; CDAI, Clinical Disease Activity Index; NCC, no comorbid conditions; OKZ, olokizumab; q2w – once every 2 weeks; q4w – once every 4 weeks; Note: p-value for interaction terms in logistic regression is presented
非 KM Figure
Fig. 3Fig. 3 Proportion of patients with at least one AE/SAE during the study. Abbreviations: ADA, adalimumab; AE, adverse event; CC, comorbid conditions; mCCI, modified Charlson comorbidity index; NCC, no comorbid conditions; OKZ, olokizumab; q2w, once every 2 weeks; q4w, once every 4 weeks; SAE, serious adverse event
非 KM Figure